^
    Back
    Association details:
    Biomarker:TOP2A overexpression
    Cancer:Multiple Myeloma
    Drug:carfilzomib (Proteasome inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Leuk Lymphoma
    Title:

    TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing

    Published date:
    10/31/2020
    Excerpt:
    TOP2A, an enzyme involved in cell cycle and proliferation, was overexpressed in carfilzomib-resistant HMCLs.
    DOI:
    10.1080/10428194.2020.1832659